Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Upgrade your Membership
Save $$$
Rumours of a Healius takeover are confirmed, but will the bid be accepted?
Nick Sundich, March 20, 2023
A Healius takeover is the market’s worst kept secret no longer. After months of rumours, Australian Clinical Labs (ASX:ACL) told its shareholders it was making a bid that, will create Australia’s largest pathology company, if the bid is accepted.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Healius takeover to create $2.1bn in value uplift
ACL told investors that a Healius takeover would unlock $95m of cost synergies, achieve a pro forma EBIT of $361m and a potential value uplift of $2.1bn if the group was to trade at the current blended forward EV/EBIT multiple of 17.5x.
It said the deal would create Australia’s largest pathology provider and psuriked the better track record of its own management compared to Healius, saying it was better equipped.
ACL is offering 0.74 of its shares for every Healius share.
A lot riding on this deal
Whatever happens of this deal is that it will take up a lot of time and attention of both companies. It is not expected to be complete until late September and is subject to ACCC and FIRB approval.
But there is huge incentive for the deal to go ahead. ACL announced its FY23 EBIT would be $68-$74m, barely a quarter of what a merged group would achieve.
Both companies, as well as Sonic Healthcare (ASX:SHL), benefited rom skyrocketing revenues during the pandemic due to PCR tests. As we return to normal, investors are skeptical even as they boast of increased revenues from their non-COVID businesses.
Whether or not the Healius takeover goes ahead, investors should keep an eye on what happens with the pathology sector more broadly.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Stocks Down Under
Average rating: 0 reviews
Blog Categories
Recent Posts
The Humm saga showed ASIC has significant powers
At the end of last month, ASIC dropped a bombshell on Humm (ASX:HUM) and its investors. For roughly 24 hours, the…
So you stock went into voluntary administration … Is it all over now or will you get any of your money back?
Voluntary administration – these are the two words that no investor wants to hear. What will happen next and will…
CET1 ratio: If you invest in banks, you need to know this
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…